Immune Regulation Interleukins & Cytokines

The function of the immune system depends in a large part on interleukins, a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behaviour. The majority of interleukins are synthesized by helper CD4+ T lymphocytes, as well as through monocytes, macrophages and endothelial cells. They promote the development and differentiation of T and B lymphocytes and hematopoietic cells. Interleukins initiate a response by binding to high-affinity receptors located on the surface of cells in a paracrine or autocrine fashion. The response of a particular cell to these cytokines depends on the ligands involved, specific receptors expressed on the cell surface and the particular signaling cascades that are activated. Interleukins can exert both pro-inflammatory and anti-inflammatory actions. Interleukins modulate growth, differentiation and activation during an immune response, which distinguishes them from chemokines, for which the main function is to direct immune cells to the site of inflammation via chemotaxis, or from interferons (IFNs), which predominantly mediate cellular response to viral infection. Despite this definition, a few interleukin members themselves can act as chemoattractants for helper T cells and others are intimately involved in the cellular response to viral pathogens. Interleukins are very important mediators of the physiological response to infections and contribute significantly to the pathophysiology of a wide range of disorders, including autoimmune diseases or immune deficiency.

Interleukin fusion receptors

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-20001AIL-1α (human) (rec.)HEK 293 cells>95%<0.01EU/µg
CHI-HR-20001AIL-1α (human) (rec.) (His)E. coli>98%<0.1EU/µg
CHI-HR-20001BIL-1β (human) (rec.) (His)E. coli>98%<0.1EU/µg


Interleukin-2 (IL-2) is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils and induces mononuclear cells to secrete IFN-γ and TNF-α. IL-2 is required for activation-induced apoptosis, an important homeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens. Low doses of recombinant IL-2 have been used for Treg cell-based immunosuppressive strategies against immune pathologies, while highdoses IL-2 have shown success in stimulating antitumor immune responses.

IL-2 (human) Superkine (Fc): Specific mutations in the recombinant IL-2 protein stabilize the structure and give it a receptorbinding conformation mimicking native IL-2 bound to CD25. This induces superior expansion of cytotoxic T cells, leading to improved antitumor responses in vivo, and elicits proportionally less toxicity by lowering the expansion of T regulatory cells.

LIT: Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’: AM. Levin, et al.; Nature 484, 529 (2012)

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-20102IL-2 (C145S Mutant) (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-21002IL-2 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22002IL-2 (human):Fc (human) (rec.) (non-lytic)NS1 cells>98%<0.06EU/µg
CHI-HF-24002IL-2 (human):Fc (human IgG4) (rec.)CHO cells>95%<5EU/mg
CHI-MF-11002IL-2 (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-12002IL-2 (mouse):Fc (mouse) (rec.) (non-lytic)NS1 cells>98%<0.06EU/µg
CHI-RR-30002IL-2 (rat) (rec.) (His)E. coli>95%<1EU/µg

Interleukin-3 to interleukin-18

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-20103IL-3 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-20104IL-4 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HR-20004IL-4 (human) (rec.) (His)E. coli>98%<0.1EU/µg
CHI-HF-21004IL-4 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22004IL-4 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MR-10004IL-4 (mouse) (rec.) (His)E. coli>98%<0.1EU/µg
CHI-MF-12004IL-4 (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-20106IL-6 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-21006IL-6 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22006IL-6 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MF-12006IL-6 (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-21006RIL-6R (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-11006RIL-6R (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-RF-311GP130IL-6Rβ [GP130] (rat):Fc (human) (rec.)HEK 293 cells>98%<5EU/mg
CHI-HF-20107IL-7 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-22007IL-7 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HR-20008IL-8 (human) (rec.) (His)E. coli>97%<0.1EU/µg
CHI-HF-22008IL-8 (human):Fc (human) (rec.) (non-lyticCHO cells>98%<0.06EU/µg
CHI-HF-20110IL-10 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HR-20010IL-10 (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HF-21010IL-10 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22010IL-10 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MF-12010IL-10 (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-21010RAIL-10Rα (human):Fc (human) (rec.)HEK 293 cells>98%<5EU/mg
CHI-HF-20112IL-12 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-21012IL-12 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-11112IL-12 (mouse):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HR-20015IL-15 (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HF-21015MIL-15 (mutant) (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-21115MBIIL-15 (mutant) (human):Fc (mouse) (rec.) (Biotin)CHO cells>98%<0.06EU/µg
CHI-HF-22017AIL-17A (human):Fc (human) (rec.) (non-lytic)HEK 293 cells>98%<5EU/mg
CHI-HR-20018IL-18 (human) (rec.) (His)E. coli>97%<1EU/µg

Interleukin-21 to interleukin-35

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-20121IL-21 (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-22021IL-21 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-24021IL-21 (human):Fc (human IgG4) (rec.)CHO cells>95%<5EU/mg
CHI-HR-20021MIL-21 (mutant) (human) (rec.) (His)E. coli>90%<1EU/µg
CHI-MF-11021IL-21 (mouse):Fc (mouse) (rec.)HEK 293 cells>98%<5EU/mg
CHI-MF-12021IL-21 (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-21021RIL-21R (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-12021RIL-21R (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-21022IL-22 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22022IL-22 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MR-10022IL-22 (mouse) (rec.) (His)E. coli>95%<1EU/µg
CHI-MF-11022IL-22 (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-12022IL-22 (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.1EU/µg
CHI-MF-11123IL-23 (mouse):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-21023RIL-23R (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-21024IL-24 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-21027IL-27 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-22027IL-27 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MF-11127IL-27 (mouse):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HR-20033IL-33 (human) (rec.) (His)E. coli>98%<1EU/µg
CHI-HF-21033IL-33 (human):Fc (human) (rec.)HEK 293 cells>98%<5EU/mg
CHI-HF-21033RIL-33R (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-11033RIL-33R (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-21035IL-35 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-11135IL-35 (mouse):Fc (human) (rec.)CHO cells>98%<0.06EU/µg

Immunomodulating cytokines and growth factors

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HR-200BMP2BMP-2 (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HF-220BMP2BMP-2 (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-MF-110CSF3CSF3 (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-210DcR3DcR3 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-201EGFEGF (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-210EGFEGF (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-220EPOEPO (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HR-200FGF2FGF-2 (human) (rec.)E. coli>95%<0.1EU/µg
CHI-HF-210FGF18FGF-18 (human):Fc (human) (rec.)HEK 293 cells>98%<5EU/mg
CHI-MF-110FGFR1FGFR1 (mouse):Fc (mouse) (rec.)HEK 293 cells>98%<5EU/mg
CHI-HF-201FLT3LFLT3 Ligand (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HR-200CSFGM-CSF (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HR-200HMGB1HMGB1 (human) (rec.) (His)E. coli>90%<0.1EU/µg
CHI-RR-300HMGB1HMGB1 (rat) (rec.) (His)E. coli>90%<0.1EU/µg
CHI-RF-311HMGB1HMGB1 (rat):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HR-200IFNGIFN-γ (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HF-201LIFLIF (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-MF-110LYVE1LYVE-1 (mouse):Fc (mouse) (rec.)HEK 293 cells>98%<5EU/mg
CHI-HF-210TGFBMTGFβ1 (mutant) (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HR-200TNFTNF-α (human) (rec.) (His)E. coli>95%<0.1EU/µg
CHI-HF-211VSIG4VSIG4 (human):Fc (mouse) (rec.)HEK 293 cells>98%<0.06EU/µg

Inflammatory chemokines

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-210CCL2CCL2 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-110CCL2CCL2 (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-210CCL4CCL4 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HR-200CCL5CCL5 (human) (rec.) (His)E. coli>98%<0.1EU/µg
CHI-HF-210CCL20CCL20 (human):Fc (human) (rec.)HEK 293 cells>95%<5EU/mg
CHI-MF-110CCL20CCL20 (mouse):Fc (mouse) (rec.)HEK 293 cells>95%<5EU/mg
CHI-HF-210CCL22CCL22 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-110CCL22CCL22 (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-210CCL24CCL24 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-210CX3CCX3CL1 (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-210SDF1ASDF-1α [CXCL12] (human):Fc (human) (rec.)HEK 293 cells>95%<5EU/mg

Stem cell factor (SCF)

SCF plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance (binding to haemapoietic stem cells), gametogenesis, mast cell development, migration and function, and in melanogenesis by activating several signaling pathways.

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-201SCFSCF (human) (rec.) (His)HEK 293 cells>95%<0.01EU/µg
CHI-HF-210SCFSCF (human):Fc (human) (rec.)CHO cells>98%<0.06EU/µg
CHI-HF-220SCFSCF (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-HF-211SCFSCF (human):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-110SCFSCF (mouse):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg
CHI-MF-120SCFSCF (mouse):Fc (mouse) (rec.) (non-lytic)CHO cells>98%<0.06EU/µg
CHI-RF-311SCFSCF (rat):Fc (mouse) (rec.)CHO cells>98%<0.06EU/µg

Transplant tolerance induction

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-210TGFBMTGFβ1 (mutant) (human):Fc (human) (rec.)CHO cells>98%<0.06EU/μg

EPO – good guy goes bad

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-220EPOEPO (human):Fc (human) (rec.) (non-lytic)CHO cells>98%<0.06EU/μg

Negative control fusion proteins

Cat. No.DescriptionSourcePurity (SDS-PAGE)Endotoxin (LAL Test)
CHI-HF-210IG1Fc (human) IgG1 Control (rec.)HEK 293 cells>98%<0.06EU/μg
CHI-HF-220IG1Fc (human) IgG1 Control (rec.) (non-lytic)HEK 293 cells>98%<0.06EU/μg
CHI-HF-210IG4Fc (human) IgG4 Control (rec.)HEK 293 cells>98%<5EU/mg
CHI-MF-110IG2AFc (mouse) IgG2a Control (rec.)HEK 293 cells>98%<0.06EU/μg
CHI-MF-120IG2AFc (mouse) IgG2a Control (rec.) (non-lytic)HEK 293 cells>98%<0.06EU/μg

Brochure: Immune Regulation Proteins

Related to:
Brands: AdipoGen Life SciencesChimerigen Laboratories
Product groups: Proteins / Signaling Molecules
News: Immune Checkpoint Proteins – The B7-CD28 Superfamily, Immune Checkpoints